CDK4/6 inhibitors in the first-line treatment of HR+/HER2-advanced stage breast cancer:a rapid health technology assessment
10.12173/j.issn.1005-0698.202404064
- VernacularTitle:CDK4/6抑制剂一线治疗HR+/HER2-晚期乳腺癌的快速卫生技术评估
- Author:
Anna LI
1
;
Zhengzheng XIA
;
Jiali CAI
;
Zhuoshi LIAN
;
Jun MENG
Author Information
1. 国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院深圳医院药学部(广东深圳 518116)
- Keywords:
CDK4/6 inhibitors;
Endocrine therapy;
HR+/HER2-advanced breast cancer;
Rapid health technology assessment
- From:
Chinese Journal of Pharmacoepidemiology
2024;33(9):1017-1029
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy,safety and economy of cyclin-dependent kinase 4/6(CDK4/6)inhibitors for the first-line treatment of hormone receptors positive(HR+),human epidermal growth factor receptor 2 negative(HER2-)advanced breast cancer(ABC)by rapid health technology assessment,and to provide evidence for clinicians and policymakers.Methods PubMed,Cochrane Library,Embase,CNKI,WanFang Data,VIP databases and the official website of health technology assessment(HTA)agency were electronically searched to collect clinical evidence and literature of CDK4/6 inhibitors in the treatment of HR+/HER2-ABC from the inception to December 31,2023.Two reviewers independently identified studies,extracted data,assessed the quality of included studies,and descriptively analyzed and summarised the results.Results A total of 33 articles were included,including 9 systematic reviews/Meta-analyses,15 pharmacoeconomic studies and 9 HTA reports.In terms of efficacy,compared with endocrine therapy alone,the addition of CDK4/6 inhibitors significantly improved progression-free survival(PFS)and overall survival(OS)in patients with HR+/HER2-ABC(P＜0.05),but there was no significant difference in efficacy among palbociclib,abemaciclib and ribociclib(P＞0.05).In terms of safety,more adverse events were observed in patients treated with CDK4/6 inhibitors when compared with endocrine therapy(P＜0.05).There was a difference in the incidence of adverse effects between the different CDK4/6 inhibitors,with palbociclib having higher incidence of haematological adverse effects(P＜0.05),and abemaciclib being more likely to cause gastrointestinal adverse reactions such as diarrhoea(P＜0.05).The economic evaluation results were variable due to differences in healthcare costs,analysis perspectives,willingness-to-pay thresholds,and study duration in different countries.Conclusion CDK4/6 inhibitors have similar efficacy in the first-line treatment of HR+/HER2-ABC patients,but there are some differences in aspects such as safety and economy.
